Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ricardo L B Costa

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
NPJ Breast Cancer|March 21, 2020
Clinical development of immunotherapies for HER2<sup>+</sup> breast cancer: a review of HER2-directed monoclonal antibodies and beyondRicardo L B Costa, Brian J Czerniecki
Breast Cancer Research and Treatment|February 9, 2018
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a reviewRicardo L B Costa, Hyo Sook Han, William J Gradishar
Case Reports in Oncology|December 28, 2017
Occult Breast Carcinoma Presenting as Scalp MetastasisRicardo L B Costa, Rubens B Costa-Filho, Marilin Rosa, et al.
Oncotarget|November 4, 2020
A systematic review and meta-analysis of selected toxicity endpoints of alpelisibMisty Shields, Qianxing Mo, Melissa Armitage, et al.
Oncology|August 1, 2023
Retrospective Study of Treatment Patterns and Natural History of Patients with T1a/b N0 Triple-Negative Breast Cancers: A Single-Institution ExperienceLangfeier Liu, Nicholas Lewis, Weihong Sun, et al.
Clinical Breast Cancer|February 22, 2023
A Real-World Data Retrospective Cohort Study of HER2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and OutcomesShahla Bari, Jiannong Li, Di Kang, et al.
Cancer Medicine|August 7, 2020
Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapySarah Talamantes, Eric Xie, Ricardo L B Costa, et al.
Oncology|November 27, 2023
A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution ExperienceHumaira Sarfraz, Shahla Bari, Junmin Whiting, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 19, 2023
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in BetweenHyo Sook Han, Praveen Vikas, Ricardo L B Costa, et al.
NPJ Breast Cancer|March 12, 2021
Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapyYael Artzy-Randrup, Tamir Epstein, Joel S Brown, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
NPJ Breast Cancer|March 21, 2020
Clinical development of immunotherapies for HER2<sup>+</sup> breast cancer: a review of HER2-directed monoclonal antibodies and beyondRicardo L B Costa, Brian J Czerniecki
Breast Cancer Research and Treatment|February 9, 2018
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a reviewRicardo L B Costa, Hyo Sook Han, William J Gradishar
Case Reports in Oncology|December 28, 2017
Occult Breast Carcinoma Presenting as Scalp MetastasisRicardo L B Costa, Rubens B Costa-Filho, Marilin Rosa, et al.
Oncotarget|November 4, 2020
A systematic review and meta-analysis of selected toxicity endpoints of alpelisibMisty Shields, Qianxing Mo, Melissa Armitage, et al.
Oncology|August 1, 2023
Retrospective Study of Treatment Patterns and Natural History of Patients with T1a/b N0 Triple-Negative Breast Cancers: A Single-Institution ExperienceLangfeier Liu, Nicholas Lewis, Weihong Sun, et al.
Clinical Breast Cancer|February 22, 2023
A Real-World Data Retrospective Cohort Study of HER2-positive, Early-Stage Breast Cancer in Patients 70 Years of Age or Older: Natural History, Treatment Patterns, and OutcomesShahla Bari, Jiannong Li, Di Kang, et al.
Cancer Medicine|August 7, 2020
Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapySarah Talamantes, Eric Xie, Ricardo L B Costa, et al.
Oncology|November 27, 2023
A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution ExperienceHumaira Sarfraz, Shahla Bari, Junmin Whiting, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 19, 2023
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in BetweenHyo Sook Han, Praveen Vikas, Ricardo L B Costa, et al.
NPJ Breast Cancer|March 12, 2021
Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapyYael Artzy-Randrup, Tamir Epstein, Joel S Brown, et al.
Pageof 3